GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DexTech Medical AB (XSAT:DEX) » Definitions » Return-on-Tangible-Asset

DexTech Medical AB (XSAT:DEX) Return-on-Tangible-Asset : -30.32% (As of Mar. 2025)


View and export this data going back to 2014. Start your Free Trial

What is DexTech Medical AB Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. DexTech Medical AB's annualized Net Income for the quarter that ended in Mar. 2025 was kr-4.97 Mil. DexTech Medical AB's average total tangible assets for the quarter that ended in Mar. 2025 was kr16.38 Mil. Therefore, DexTech Medical AB's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 was -30.32%.

The historical rank and industry rank for DexTech Medical AB's Return-on-Tangible-Asset or its related term are showing as below:

XSAT:DEX' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -119.93   Med: -58.36   Max: -14.84
Current: -25.02

During the past 12 years, DexTech Medical AB's highest Return-on-Tangible-Asset was -14.84%. The lowest was -119.93%. And the median was -58.36%.

XSAT:DEX's Return-on-Tangible-Asset is ranked better than
59.6% of 1500 companies
in the Biotechnology industry
Industry Median: -36.245 vs XSAT:DEX: -25.02

DexTech Medical AB Return-on-Tangible-Asset Historical Data

The historical data trend for DexTech Medical AB's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DexTech Medical AB Return-on-Tangible-Asset Chart

DexTech Medical AB Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -91.74 -119.93 -26.50 -14.84 -20.69

DexTech Medical AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -25.66 -25.04 -23.81 -21.80 -30.32

Competitive Comparison of DexTech Medical AB's Return-on-Tangible-Asset

For the Biotechnology subindustry, DexTech Medical AB's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DexTech Medical AB's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DexTech Medical AB's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where DexTech Medical AB's Return-on-Tangible-Asset falls into.


;
;

DexTech Medical AB Return-on-Tangible-Asset Calculation

DexTech Medical AB's annualized Return-on-Tangible-Asset for the fiscal year that ended in Jun. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Jun. 2024 )  (A: Jun. 2023 )(A: Jun. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Jun. 2024 )  (A: Jun. 2023 )(A: Jun. 2024 )
=-4.706/( (25.82+19.68)/ 2 )
=-4.706/22.75
=-20.69 %

DexTech Medical AB's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=-4.968/( (16.687+16.082)/ 2 )
=-4.968/16.3845
=-30.32 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2025) net income data.


DexTech Medical AB  (XSAT:DEX) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


DexTech Medical AB Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of DexTech Medical AB's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


DexTech Medical AB Business Description

Traded in Other Exchanges
N/A
Address
Dag Hammarskjolds Vag 34A, Uppsala, SWE, 752 37
DexTech Medical AB develops candidate medications with applications within urological oncology, for prostate cancer. Its medication candidates include GuaDex, OsteoDex, and SomaDex, among others. The company conducts operations in medical research with the development of new drug candidates mainly in urological oncology, but also other cancer diseases and for non-malignant diseases. The company has a well built clinical base with valuable specialist expertise from research laboratories and manufacturing to clinical oncology.